BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests
Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of KRYPTOR automated diagnostic solutions, has the non-exclusive rights to incorporate Lumi4(R) technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down’s Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.
“Lumiphore’s goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore’s new reporter technology,” said Steve Blose Lumiphore’s Chief Business Officer.
“Using Lumi4(R)-Tb in the reader technology of our diagnostic tests will provide multiple benefits for BRAHMS. Thus we will take Lumi4(R)-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats,” said
BRAHMS’ KRYPTOR analysis systems can currently perform various analyses in random-access operations using TRACE (Time Resolved Amplified Cryptate Emission) technology, based on Forster resonance energy transfer (FRET). – FRET uses two fluorophores as a donor and an acceptor. The energy transfer between these two occurs when in nanometer scale proximity, which allows accurate measurement of molecular interactions. BRAHMS is using Nobel Prize winning cyrptand donor chemistry (
Lumi4(R) complexes are a new class of fluorescent-metal lanthanide detection reagents based on technology patented by Professor
This is the fourth strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International (www.htrf.com/company/partners/) for the drug discovery research market; Echelon Biosciences Inc. (www.echelon-inc.com) for novel cancer assays involving phospholipid signaling; and Biophor Diagnostics Inc. for diagnostic tests for drugs of abuse.
About BRAHMS Aktiengesellschaft
The BRAHMS AG conducts researches, develops, produces and markets innovative diagnostic biomarkers. It is one of the three largest biotechnology companies in
About Lumiphore, Inc.
Media Contact Lumiphore, Inc. Stephen Blose Chief Business Officer + 1 415-318-4457 firstname.lastname@example.org www.lumiphore.com Cezanne, SAS Emmanuel Bois President +33 466 365 236 email@example.com www.cezanne.fr BRAHMS Aktiengesellschaft Ingo Buchholzer Public Relations Manager + 49 3302 883-637 firstname.lastname@example.org www.brahms.de
SOURCE Lumiphore, Inc.; Cezanne, SAS; BRAHMS Aktiengesellschaft